Survodutide Guide
The GLP-1/Glucagon Dual Agonist for
Complete guide to Survodutide (BI 456906) - Boehringer Ingelheim
What Is Survodutide?
Survodutide (BI 456906) is a dual receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates both GLP-1 receptors (like Ozempic) and glucagon receptors—a unique combination that targets both appetite and metabolism.
Why glucagon? While glucagon is often associated with raising blood sugar, when combined with GLP-1, it dramatically increases energy expenditure and promotes fat burning—especially in the liver. This makes Survodutide particularly promising for fatty liver disease.
Administration: Once-weekly subcutaneous injection, similar to other GLP-1 medications.
The Dual Mechanism
GLP-1 Agonism
Reduces appetite and food intake. Slows gastric emptying. Improves insulin secretion. Lowers blood sugar. Proven weight loss mechanism
Glucagon Agonism
Increases energy expenditure. Promotes fat oxidation. Dramatically reduces liver fat. Improves lipid profiles. Enhances weight loss beyond GLP-1 alone
Survodutide vs Mounjaro
While both are dual agonists, they target different second receptors. Mounjaro = GLP-1 + GIP (enhances insulin). Survodutide = GLP-1 + Glucagon (burns fat, especially liver fat). This makes Survodutid
Breakthrough MASH Results
MASH Resolution
83%
In Phase 2 trials, 83% of patients on the highest dose achieved MASH resolution without worsening fibrosis. This is the highest rate ever seen in a MA
Fibrosis Improvement
52%
52% of patients showed fibrosis improvement by at least one stage. Fibrosis (liver scarring) was previously considered largely irreversible—this sugge
Liver Fat Reduction
87%
Patients experienced up to 87% relative reduction in liver fat content. The glucagon component specifically drives fat out of the liver, addressing th
Weight Loss Results
Average Weight Loss
18.7%
At the highest dose (4.8mg weekly), participants lost an average of 18.7% of their body weight over 46 weeks—comparable to tirzepatide (Mounjaro).
Many Participants
>20%
Expected Dosing Schedule
Weeks 1-4
0.6mg weekly
Weeks 5-8
1.2mg weekly
Weeks 9-12
2.4mg weekly
Week 13+
4.8mg weekly
Side Effects
Common (GI-Related)
Nausea (most common). Vomiting. Diarrhea. Decreased appetite. Constipation
Glucagon-Related Considerations
Safety note: The GLP-1 component effectively prevents glucagon from raising blood sugar. In trials, Survodutide improved glycemic control despite the glucagon component.
Development Timeline
2023:
Phase 2 results published (obesity and MASH)
2024-2026:
Phase 3 trials ongoing for obesity and MASH
2026:
Expected Phase 3 completion
2027:
Potential FDA approval (obesity and/or MASH)
Who Will Benefit Most?
Ideal Candidates
Patients with fatty liver disease (MASH/NAFLD). Obesity with elevated liver enzymes. Those who haven't responded well to other GLP-1s. Patients wanting metabolic + liver benefits. Type 2 diabetics wit
The MASH Opportunity
MASH affects millions and can progress to cirrhosis and liver cancer. With no approved treatments, Survodutide could be the first FDA-approved medication for this condition.
Vital Protocol FAQs
Will Survodutide raise my blood sugar?
No. While glucagon alone raises blood sugar, the GLP-1 component in Survodutide effectively counteracts this. Clinical trials showed improved glycemic control, not worsened. The combination is designe
Is Survodutide only for people with liver disease?
No. Survodutide is being developed for both obesity AND MASH. You don't need liver disease to potentially benefit from its weight loss effects. However, if you do have fatty liver, Survodutide may off
How does Survodutide compare to Retatrutide for liver disease?
Both show excellent liver benefits due to their glucagon components. Survodutide's Phase 2 MASH data (83% resolution) is slightly ahead of Retatrutide's liver data, though direct comparisons are diffi
When will Survodutide be available?
Phase 3 trials are ongoing. If successful, FDA submission could occur in 2026, with potential approval in 2027. MASH indication may be approved before or alongside obesity indication.
Guide FAQs
Complete guide to Survodutide (BI 456906) - Boehringer Ingelheim
Yes. Shotlee supports tracking Survodutide doses, side effects, and health metrics. It is free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Survodutide research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Survodutide, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Survodutide protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Survodutide data in Shotlee to identify which combinations drive your best results.
References
Track Your Survodutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free